Picture loading failed.

Anti-CD19 therapeutic antibody (Pre-made Denintuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Denintuzumab mafodotin (INN; development codes SGN-19A or SGN-CD19A) is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-139-1mg 1mg Inquiry
GMP-Bios-ab-139-10mg 10mg Inquiry
GMP-Bios-ab-139-100mg 100mg Inquiry
GMP-Bios-ab-139-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD19 therapeutic antibody (Pre-made Denintuzumab biosimilar,Whole mAb ADC)
INN Name Denintuzumab
FormatWhole mAb ADC
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesSeattle Genetics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma
Development Techna